BioSpace News Archive

OneOncology, the platform for the nation’s leading independent oncology practices, announced two nationally renowned keynote speakers for the first OneOncology Annual Conference for providers scheduled for November 11-13 in Nashville.

The latest market analysis report published by Reports and Data, titled ‘Global Paroxysmal Nocturnal Hemoglobinuria Market – Forecast to 2030,’ thoroughly examines the Paroxysmal Nocturnal Hemoglobinuria industry to provide essential data & information for the targeted readers.

India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (“USPTO”) issued a second patent (#11,446,276) for the treatment of Alzheimer’s disease entitled “Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimer’s disease.”

Biomind Labs Inc. is pleased to announce the completion of dose administration of 30 healthy subjects in the Company’s Phase II trial of its novel drug candidate BMND01 for Treatment-Resistant Depression.

XOMA Corporation announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the third planned interim analysis of the Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection.

On track to report topline data from the Pivotal Phase 3 SIERRA trial for Iomab-B in Q4 2022 Overall survival data from the Actimab-A CLAG-M combination trial expected in Q4 2022.

MaxCyte, Inc. announced that it has relocated its headquarters to 9713 Key West Avenue in Rockville, Maryland, 20850, within Maryland’s I-270 Biotech Corridor.

electroCore, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued four patents related to its non-invasive vagus nerve stimulation (nVNS) and other technologies, including the following patents: U.S. Patent No. 11,406,825 entitled “Mobile Phone for Treating a Patient with Dementia” issued on August 9, 2022.

Cumulus Neuroscience today appointed Aman Bhatti, MD, as Chief Executive Officer (CEO).